Roche's RoActemra receives EU positive opinion for treatment of RA
This article was originally published in Scrip
Executive Summary
Roche'sRoActemra (tocilizumab), a fully humanised interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, has received a positive recommendation from the EU's CHMP for the treatment of moderate to severe rheumatoid arthritis (RA), in combination with methotrexate in adults who have either responded inadequately to, or who are intolerant to, previous therapy with one or more disease modifying antirheumatic drugs (DMARDs) or TNF antagonists such as Wyeth'sEnbrel (etanercept) and Centocor/Schering-Plough'sRemicade (infliximab).
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.